- Home
- SLGL vs INKT Comparison
SLGL vs INKT Comparison
Compare SLGL & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- INKT
- Stock Information
- Founded
- SLGL 1997
- INKT 2017
- Country
- SLGL Israel
- INKT United States
- Employees
- SLGL N/A
- INKT N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SLGL Health Care
- INKT Health Care
- Exchange
- SLGL Nasdaq
- INKT Nasdaq
- Market Cap
- SLGL 30.9M
- INKT 34.9M
- IPO Year
- SLGL 2018
- INKT 2021
- Fundamental
- Price
- SLGL $0.90
- INKT $1.01
- Analyst Decision
- SLGL Strong Buy
- INKT Strong Buy
- Analyst Count
- SLGL 2
- INKT 2
- Target Price
- SLGL $5.00
- INKT $6.50
- AVG Volume (30 Days)
- SLGL 1.4M
- INKT 226.6K
- Earning Date
- SLGL 03-12-2025
- INKT 11-14-2024
- Dividend Yield
- SLGL N/A
- INKT N/A
- EPS Growth
- SLGL N/A
- INKT N/A
- EPS
- SLGL N/A
- INKT N/A
- Revenue
- SLGL $11,707,000.00
- INKT N/A
- Revenue This Year
- SLGL $772.97
- INKT N/A
- Revenue Next Year
- SLGL N/A
- INKT N/A
- P/E Ratio
- SLGL N/A
- INKT N/A
- Revenue Growth
- SLGL 869.93
- INKT N/A
- 52 Week Low
- SLGL $0.33
- INKT $0.46
- 52 Week High
- SLGL $1.65
- INKT $1.90
- Technical
- Relative Strength Index (RSI)
- SLGL 48.02
- INKT 66.31
- Support Level
- SLGL $0.83
- INKT $0.82
- Resistance Level
- SLGL $1.40
- INKT $0.91
- Average True Range (ATR)
- SLGL 0.21
- INKT 0.14
- MACD
- SLGL -0.04
- INKT 0.02
- Stochastic Oscillator
- SLGL 10.70
- INKT 63.33
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.